- New data supports the potential role of Artificial Intelligence
(AI) in predicting patients’ response to immunotherapies in advance
of their treatment.
- AI models demonstrated 70 to 80 percent accuracy in predicting
both the likelihood of efficacious response and specific
immune-related toxicities.
- Enables clinicians to match patients to the most effective
treatment sooner, potentially avoiding unnecessary side effects and
cost, and driving personalized and precise care.
GE HealthCare’s Artificial Intelligence (AI) models predict
patient response to immunotherapies with 70 to 80 percent
accuracy1, based on a pan-cancer cohort, according to findings to
be presented at the Society for Immunotherapy of Cancer (SITC) in
San Diego, U.S., by GE HealthCare, Vanderbilt University Medical
Center (VUMC) and the University Medicine Essen (UME), Germany.
Originally developed based on a cohort of over 3,000 immunotherapy
patients from VUMC and subsequently validated on a cohort of 4,000
patients from UME, the AI models predict efficacy outcomes and the
likelihood of an individual patient developing an adverse reaction.
This could enable precision care by unlocking the potential for
clinicians to select the appropriate personalized treatment pathway
sooner while potentially sparing unnecessary side effects and
cost.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231101659257/en/
T cells helping immune system to fight
cancer cells in response to immunotherapies (Photo: Business
Wire)
Immunotherapies use the immune system to recognize and attack
cancer cells and can be more effective than traditional treatments,
but response rates are often low and side effects can be severe.2
In addition to the potential benefits of these AI models in
clinical use, with roughly 5,000 immunotherapies in development
today3, selecting patients more likely to respond could also help
drug developers to speed up and increase the likelihood of success
of clinical trials. After regional regulatory approvals, GE
HealthCare plans to commercialize the models for use both in
pharmaceutical drug development and for clinical decision
support.
To develop the AI models, GE HealthCare and VUMC retrospectively
analyzed and correlated the immunotherapy treatment response of
thousands of VUMC cancer patients, with their deidentified
demographic, genomic, tumor, cellular, proteomic, and imaging data.
The models presented at SITC use only routinely acquired data from
the patient's electronic health record (EHR) as inputs, enabling
versatility and scalability in their potential application.
“Immunotherapy can offer significant benefits for patients but
given the current unpredictability of some reactions to treatment,
it can also be associated with increased morbidity and cost. These
results pave the way for the ability to better select which
patients should benefit and which would be better suited to an
alternative form of treatment,” said Travis Osterman, DO, MS,
Associate Vice President for Research Informatics and Associate
Chief Medical Information Officer for Vanderbilt University Medical
Center, and Director of Cancer Clinical Informatics at
Vanderbilt-Ingram Cancer Center.
"In our joint work, we have shown that the AI models are
effective across both sides of the Atlantic, paving the way for
real world applications that could offer significant benefits for
cancer patients treated with immunotherapies." said Jens Kleesiek,
MD, PhD, Head of the Medical Machine Learning Department at the
Institute for AI in Medicine and Associate Director of the West
German Cancer Center of the University Medicine Essen.
“These results are a promising development in the journey
towards precision care, selecting treatment pathways based on the
individual patient’s likely response. We are keen to partner with
pharmaceutical companies, researchers, and clinicians to optimize
and apply our AI models in therapy development and in clinical
practice in a longer term,” said Julia Casey, General Manager
Molecular Imaging at GE HealthCare’s Pharmaceutical Diagnostics
segment.
The AI models are an integral part of GE HealthCare’s
immuno-oncology development portfolio which includes the
development of novel PET tracers. The company recently announced
the first patient scanned in a Phase I clinical trial of a
first-of-its kind fluorine-18 PET radiopharmaceutical specific for
CD8. Almost all immunotherapies work by activating CD8+ T cells - a
subpopulation of white blood cells which fight cancer - both within
and outside a tumor.
GE HealthCare’s Pharmaceutical Diagnostics segment is a global
leader in imaging agents used to support around 100 million
procedures per year globally, equivalent to three patient
procedures every second. Its Molecular Imaging portfolio combines
established proprietary products across cardiology, neurology, and
oncology, with an innovative pipeline, all aimed at enabling
better-informed diagnosis and monitoring for improved therapy
decision-making and clinical outcomes.
About GE HealthCare Technologies Inc. GE HealthCare is a
leading global medical technology, pharmaceutical diagnostics, and
digital solutions innovator, dedicated to providing integrated
solutions, services, and data analytics to make hospitals more
efficient, clinicians more effective, therapies more precise, and
patients healthier and happier. Serving patients and providers for
more than 100 years, GE HealthCare is advancing personalized,
connected, and compassionate care, while simplifying the patient’s
journey across the care pathway. Together our Imaging, Ultrasound,
Patient Care Solutions, and Pharmaceutical Diagnostics businesses
help improve patient care from diagnosis, to therapy, to
monitoring. We are an $18.3 billion business with 50,000 employees
working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, and Insights for the
latest news, or visit our website https://www.gehealthcare.com/ for
more information.
About Vanderbilt University Medical Center Vanderbilt
University Medical Center (VUMC) is the largest comprehensive
research, teaching and patient care health system in the Mid-South
region of the U.S., with the highest ranked adult and children’s
hospitals in the Southeast by U.S. News & World Report. Based
in Nashville, Tennessee, VUMC sees more than 3.2 million patient
visits per year in over 180 ambulatory locations, performs 91,000
surgical operations and discharges 79,000 inpatients from its
main-campus adult, children’s, psychiatric and rehabilitation
hospitals and three regional community hospitals. The Medical
Center is the largest non-governmental employer of Middle
Tennesseans, with nearly 40,000 staff, including more than 3,000
physicians, advanced practice nurses and scientists appointed to
the Vanderbilt University faculty. For more information and the
latest news follow VUMC on Facebook, LinkedIn, Twitter and in the
VUMC Reporter.
About The University Medicine Essen (UME) Including its
four subsidiary hospitals, University Medicine Essen comprises a
total of 32 clinics and 24 institutes. Around 10,000 experts
provide their know-how for more than 70,000 inpatients and 300,000
outpatients per year. Several hundred physicians and scientists
work together at the West German Cancer Center Essen, the
comprehensive cancer center of the University Hospital Essen, to
offer cancer patients innovative interdisciplinary treatment
programs and individualized therapies. With standout categories in
electronic functionalities and artificial intelligence, UME is
ranked in the top 20 of Newsweek World's Best Smart Hospitals
2023.
1 Poster “Evaluation of Machine Learning Models to Predict
Efficacy and Toxicity of Immune Checkpoint Inhibitors Using an
External Real-World Pan-Cancer Cohort” to be presented at SITC 38th
Annual meeting 2
https://www.hopkinsmedicine.org/inhealth/about-us/immunotherapy-precision-medicine-action-policy-brief#:~:text=It%20doesn't%20work%20for,are%20about%2015%20to%2020%25.
Accessed on October 31, 2023. 3 Shankar L. et al. Harnessing
imaging tools to guide immunotherapy trials: summary from the
National Cancer Institute Cancer Imaging Steering Committee
workshop. Lancet Oncology 2023; 24(3): e133-e143. doi:
10.1016/S1470-2045(22)00742-2
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231101659257/en/
GE HealthCare Media Contact: Mathilde Bouscaillou +33 647
008 271 Mathilde.bouscaillou@ge.com Vanderbilt University
Medical Center Media Contact: John Howser 615-322-4747
John.howser@vumc.org University Medicine Essen Media
Contact: Achim Struchholz Achim.Struchholz@uk-essen.de
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Jun 2024 to Jul 2024
GE HealthCare Technologies (NASDAQ:GEHC)
Historical Stock Chart
From Jul 2023 to Jul 2024